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Edited by Hans-Dieter KlenkAbstract SARS-associated coronavirus was identiﬁed as the eti-
ological agent of severe acute respiratory syndrome and a large
virus pool was identiﬁed in wild animals. Virus generates drug
resistance through fast mutagenesis and escapes antiviral treat-
ment. siRNAs targeting diﬀerent genes would be an alternative
for overcoming drug resistance. Here, we report eﬀective siRNAs
targeting structural genes (i.e., spike, envelope, membrane, and
nucleocapsid) and their antiviral kinetics. We also showed the
synergistic eﬀects of two siRNAs targeting diﬀerent functional
genes at a very low dose. Our ﬁndings may pave a way to develop
cost eﬀective siRNA agents for antiviral therapy in the future.
 2006 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Severe acute respiratory syndrome (SARS) spread to over
thirty countries and infected over 8400 individuals and killed
813 lives around the world in 2003 (www.who.int/csr/sars/
en). Isolated SARS cases were reported in Taiwan late 2003
and China early 2004. A novel coronavirus (SARS-associated
coronavirus, SCoV) was identiﬁed as the agent of SARS [1–6].
SCoV can produce a similar type of pneumonia in monkeys
and other animals [7–10]. There is a ScoV-like viral pool in a
large number of wild animals, and it is likely that SCoV was
originated from these wild animals and later transmitted to hu-
mans [8–16]. SARS can be transmitted through the airway or
nasal passage, through urine, water, or domestic pets
[2,9,10,17–19]. The identiﬁcation of SCoV-like virus from
beasts and bats indicates further outbreaks of this disease are
diﬃcult to be ruled out. No vaccine or speciﬁc eﬀective antivi-
ral method has yet been developed to treat this disease.*Corresponding author. Fax: +852 2635 4977.
E-mail address: hkung@cuhk.edu.hk (H. Kung).
1 These authors contributed equally.
0014-5793/$32.00  2006 Published by Elsevier B.V. on behalf of the Feder
doi:10.1016/j.febslet.2006.03.066SCoV is a large, enveloped, positive-stranded RNA virus
and its genome is composed of 30-kb nucleotides [19,20].
The organization of the genome is typical of the coronaviruses,
following the characteristic gene order 5 0-replicase (rep), spike
(S), envelope (E), membrane (M), and nucleocapsid (N)-3 0
(Fig. 1). The non-structural rep gene comprises 21-kb of the
genome encoding two polyproteins (encoded by ORF1a and
ORF1b) that undergo cotranslational proteolytic processing.
The rep gene products are translated from genomic RNA,
and play key roles in viral replication and viral gene transcrip-
tion [19,20]. These structural proteins are translated from
subgenomic mRNA, which are synthesized through a discon-
tinuous transcription process [21–25]. The spike glycoprotein
has been shown to be a viral ligand, which plays a critical role
in virus binding to its receptor ACE2 or CD209L for viral en-
try into the host cells [26,27]. Based on the peptide protection
study, we showed that spike protein is a good target for pre-
vention of viral infection [28,29]. The nucleocapsid protein
has been shown to play a role in viral genome package, tran-
scriptional regulation of viral genes, and intracellular signaling
[30]. The envelope protein and membrane protein are involved
in viral package, viral secretion and virus–cell interactions.
Small interfering RNA (siRNA) and short hairpin RNA
(shRNA) are potent agents for silencing gene expression, viral
infection and replication in a sequence-speciﬁc manner [31–35].
Replicase has long been the favorite target for antiviral drug
development. We were the ﬁrst group to demonstrate that siR-
NAs targeted on the rep gene potently inhibited SCoV infec-
tion and replication [36]. However, recent studies revealed
that viruses could easily escape siRNA targeting through fast
mutagenesis [37,38]. Therefore, identiﬁcation of multiple eﬀec-
tive siRNAs targeting diﬀerent sites or functional genes of
ScoV would be an alternative for the treatment of possible
SARS outbreak in the future.2. Materials and methods
2.1. siRNA design, synthesis, and screening
siRNAs were rationally designed according to new strategies as de-
scribed recently [31,35]. The candidate siRNAs scored to six or more
were selected and subjected to a BLAST search against GenBank to en-
sure that they are unique to SCoV genome sequences only. Three siR-ation of European Biochemical Societies.
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Fig. 1. The diagram of the eﬀective siRNA’s targeting sites. SCoV genomic RNA is composed of 30-kb nucleotides. The replicase gene, which
comprises about 60% of the genome, encodes two polyproteins that undergo cotranslational proteolytic processing. The downstream sequence of the
replicase gene encodes four structural proteins (spike, envelope, membrane, and nucleocapsid) and multiple potential nonstructure proteins (not
shown). The SCoV replicase gene products are directly translated from genomic RNA, while the remaining viral proteins are translated from
subgenomic transcripts. The target sites of the eﬀective siRNAs are shown by arrows. Si- = SARSi-.
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Proligo BioTech Ltd. (Paris, France). Their antiviral eﬀects were detec-
ted by cytopathic eﬀects (CPE) assay and those siRNAsmarkedly inhib-
itedCPEswere chosen for this study.The sense-strand sequences of these
siRNAsareCACUGAUUCCGUUCGAGAUC(SARSi-S); CGUUU-
CGGAAGAAACAGGUAC (SARSi-E); CAAGCCUCUUCUCG-
CUCCUC (SARSi-N); UGCUUGCUGCUGUCUACAG (SARSi-M1);
and GUGGCUUAGCUACUUCGUUG (SARSi-M2). The sequences
are corresponding to nucleotide 23150–23169, 26113–26133, 28648–
28667, 26576–26594, and 26652–26671 of GZ50 stain (Accession num-
ber AY304495), respectively (Fig. 1). SARSi-R, the most potent siRNA
targeting rep gene (GCACUUGUCUACCUUGAUG, Ref. [36]), was
used as positive control in this study. A siRNA targeting luciferase
mRNA [33], was used as a SARS-unrelated siRNA control. All the siR-
NAs were labeled with ﬂuorescence at 5 0-end of the sense strands.2.2. Cell culture, transfection and SCoV infection
Fetal rhesus kidney (FRhk-4) cells were cultured and maintained in
MEM medium with 10% fetal bovine serum (FBS, Invitrogene).
Around 5000 cells were set in each well of a 96-well dish for viral infec-
tion and replication assay. The cells were transfected either without
(negative control) or with siRNA at standard concentration
(200 nM) using OligoFectmine (Invitrogen, CA), in accordance with
the manufacturer’s instructions. Six hours after transfection, the cul-
ture medium was removed and the cells were washed twice with PBS
before SCoV infection. One hundred microliters of SARS-associated
coronavirus (GZ50) diluted in MEM with 1% FBS was added to the
transfected cells (multiplicity of infection 0.05). The cytopathic eﬀects
(CPE) were observed and recorded under phase-contrast microscope
36 h post-infection [28,36,40]. The experiments were performed in trip-
licate and repeated at least three times.2.3. Quantitative RT-PCR
Total intracellular RNA was isolated using RNeasy Mini kit (Qia-
gene, Germany) in accordance with the manufacturer’s instructions.
The reverse-transcription experiments were performed using Thermo-Script RT-PCR systems (Invitrogen, CA). Real-time PCR was then
performed using the forward primer 5 0-GAAGGACCTACTA-
CATGTGGGTACCTA-30 (GZ50 strain, nt 1303–1329), the reverse
primer 5 0-AACACTATGCTCAGGTCCAATCTCT-3 0 (nt 1401–
1377) and the ﬂuorescent probe 5 0-(FAM)-CTAATGCTGTAGT-
GAAAATGCCATGTCCTGC-(TRMA)-3 0 (nt 1334–1364). The prim-
ers and probe bind the 5 0-region of replicase 1 A that permit us to
measure the viral genomic RNA copies. Two microliters of the RT
product (template) was used for each reaction. Forward and reverse
primers (ﬁnal concentration 900 nM) and the ﬂuorescent probe (ﬁnal
concentration 250 nM) were mixed with Master Mix (ABI, USA)
and real-time quantiﬁcation was carried out using an ABI7900 Se-
quence Detection System. The PCR conditions were: 50 C for
5 min, 95 C for 10 min, then 40 cycles of 95 C for 15 sec and 61 C
for 1 min [28,41].
2.4. Titration of viral titers
The conditioned medium from infected cells was diluted at 10-fold
serial in MEM with 1% FBS and used for infecting cells according
to the standard protocol. Brieﬂy, cells were set in 96-well dishes sixteen
hours before infection. Seventy-two hours post-infection, CPE was ob-
served and recorded under phase-contrast microscopy 72 h post-infec-
tion, and infectious viral titer was calculated [28,36,40,41].3. Results
3.1. Protection of cytopathic eﬀects (CPE) caused by SCoV
infection and replication
Virus would easily escape antiviral treatment with a drug
targeting a single site or gene via fast mutagenesis [37,38]. As
there is a large SCoV-like virus pool in a number of wild ani-
mals [8–16], it would be useful to develop multiple cost-eﬀec-
tive and speciﬁc agents for clinical use in the future.
Apparently, development of siRNAs against multiple genes
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Fig. 3. Reduction of intracellular viral genomic RNA copies by
siRNA. The cellular RNA was isolated and quantitative RT-PCR
experiments were conducted 24 h post-infection. The experiments were
performed in triplicate and repeated at least three times. Detection
revealed that these siRNAs reduced viral replication eﬀectively
(student’s t test, P < 0.01). The values (mean ± S.E.) were shown in a
typical experiment. The values are: GL2i, 1.69 · 106 ± 4.7 · 103;
SARSi-R, 1.2 · 105 ± 5.5 · 102; SARSi-S, 2.5 · 105 ± 1.0 · 105; SAR-
Si-E, 4.4 · 105 ± 1.0 · 105; SARSi-M1, 3.8 · 105 ± 2.2 · 105; SARSi-
M2, 3.1 · 105 ± 1.2 · 105; and SARSi-N, 5.7 · 105 ± 1.5 · 105.
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design protocols [35,39], we systematically designed and syn-
thesized multiple siRNAs targeting each structural gene (S,
E, M, and N). Then we detected their antiviral activities by
CPE assay (described below) and selected the most eﬀective
siRNAs for this study (Fig. 1).
Monkey kidney FRhk-4 cells were used for SCoV infection
and replication assay. Cells were set in 96-well dishes and
transfected with or without siRNAs. The transfection eﬃ-
ciency was monitored under ﬂuorescent microscopy. It ap-
peared almost all the cells were transfected. The cells were
infected with SCoV 6 h after transfection, and CPE was mon-
itored under phase-contrast microscopy. We recorded CPE at
36 h post-infection using phase-contrast microscopy [28,36].
The non-infected cells were healthy, and showed clear round
shapes (Fig. 2, panel I), while the infected cells displayed long-
er shapes, and some cells even ﬂoated away (Fig. 2, panel II).
No toxicity or CPE was discovered when cells were transfected
with a siRNA (GL2i) targeting unrelated luciferase mRNA
(Fig. 2, panel III) or SCoV RNA without virus infection (data
not shown). Cytopathic eﬀects appeared when cells were trans-
fected without or with GL2i and infected with SCoV (Fig. 2,
panels II and IV). As eﬀective siRNA targeting replicase
(Fig. 2, panel V), cells transfected with eﬀective siRNA target-
ing structural genes (SARSi-S, SARSi-E, SARSi-M1, SARSi-
M2 and SARSi-N, Fig. 2, panels VI–X) protected from CPE.
3.2. Reduction of viral genomic RNA copies
We further characterized their antiviral eﬀects of individual
eﬀective siRNA by determination of the copy numbers of
intracellular viral genomic RNA using real-time RT-PCR as-
says. We transfected the cells with siRNAs, and infected them
with SCoV 6 hours after transfection. We then isolated the to-
tal cellular RNA from the infected cells 24 h post-infection and
quantiﬁed the viral genomic copies by real-time PCR. We
found that the intracellular viral RNA level was reduced byFig. 2. Inhibition of CPE by siRNAs. Cytopathic eﬀects: FRhk-4 cells were
infected with SCoV (II and IV–VIII). The photos were taken under phase-co
cells.67.3–83.3% (83.3% by SARSi-S, 74.0% by SARSi-E, 77.5%
by SARSi-M1, 81.7% by SARSi-M2, and 67.3 % by SARSi-
N) compared with the GL2i control at standard concentration
(200 nM) (Fig. 3). These results indicate that siRNAs potently
inhibited SCoV RNA replication.
3.3. Kinetics of intracellular viral genomic RNA
It is very interesting for us to understand viral kinetics of
siRNA targeting SCoV. To our knowledge, no one has been
addressed viral kinetic of any eﬀective siRNA against SCoV.
The intracellular RNA level is of course a key parameter for
monitoring the kinetics of viral replication. Therefore, we car-
ried out quantitative RT-PCR experiments to determine SCoV
genomic RNA copies in the infected cells at diﬀerent time
points. The infected cells became sever sick 24 h post-infection,
therefore, we measured the intracellular viral RNA copies attransfected with (III–VIII, 200 nM) or without (I and II) siRNAs and
ntrast microscope at 36 h post-infection. The arrows show cytopathic
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Fig. 4. The kinetics of viral genomic RNA. FRhk-4 cells were
transfected with siRNAs and infected with SCoV. At 1 h post-
infection the medium containing viruses was removed. The cells were
then washed twice with PBS containing 5 mM EDTA, and cultured in
MEM medium containing 1% FBS. Total RNA was isolated, and viral
genomic copies were quantiﬁed by real-time RT-PCR.
M.-L. He et al. / FEBS Letters 580 (2006) 2414–2420 2417time point 1, 6, 12, 18, and 24 h. At time point 1 h, we isolated
total RNA from infected cells and measured the viral genomic
RNA copies by quantitative RT-PCR. We found that the
intracellular viral RNA copies were almost same regardless
of transfection with or without siRNAs, indicating that trans-
fected siRNA did not prevent virus entry. Therefore, we deﬁne
the relative copy number as 1. In the control samples, the
intracellular viral genomic RNA copies increased over 200
times within 5 h, and increased another 25 times in the follow-
ing 6 h, as a result, the viral genomic RNA copies were ampli-
ﬁed over 5000-fold in FRhk-4 cells in the ﬁrst 12 h. However,
the viral genomic RNA copies were only increased 2 fold either
from time point 12 to 18 h or from time point 18 to 24 h (Table
1). These results suggested that the viral reproduction dis-
played two phases in FRhk-4 cells, i.e., fast replication phase
(1–12 h) and viral package and secretion phase (12–24 h).
In the following 5 h, the viral genomic RNA level was only re-
ducedby 2–3-folds by all the tested siRNAs (Table 1). In the next
6 h (6–12 h), the RNA copies were signiﬁcantly reduced over 57-
folds by SARSi-R. This strong inhibition was maintained until
18 h and the viral genomic RNA copies were almost unchanged
(24 h post-transfection). Eighteen hours post-infection, the viral
genomic RNA copies increased rapidly, and the inhibition was
dropped to 13-folds at time point 24 h (Table 1). For siRNA tar-
geting S gene (SARSi-S), about ﬁvefold inhibition was observed
at time point 12 and 18 h, but only about 3-fold inhibition was
observed at time point 24 h. For siRNAs targeting other struc-
tural genes, the viral genomic RNA copies were only reduced
by 2–3-folds at all time points (Fig. 4).
3.4. Inhibition of viral reproduction in a dose-dependent manner
It remained to be determined whether the reduced RNA lev-
els by siRNAs targeted on diﬀerent regions had similar impacts
on infectious viral titers, i.e., viral reproduction. The living
SARS-associated coronavirus contains intact viral genomic
RNA and functional viral proteins. The factors such as the eﬃ-
ciency and correction of viral RNA replication, viral package
and secretion determine the infectious viral titers.
To elucidate the eﬀects of siRNAs on viral titers, we per-
formed virus infectivity assay experiments. At 1 h post-infec-
tion we removed the media and washed the cells twice with
PBS containing 10 mM EDTA. Fresh MEM medium contain-
ing 1% FBS was then added to the cells, which were incubated
for 24 h. The viral titers in the conditioned media were mea-
sured by TCID50 assay. We found 200 nM of siRNAs mark-
edly reduced infectious viruses which were secreted and
accumulated in the culture media (data not shown).
To determine whether SCoV was inhibited by siRNAs in a
dose-dependent manner, diﬀerent amounts of SCoV-speciﬁc
siRNAs were transfected into FRhk-4 cells before viral infec-Table 1
Relative intracellular viral genomic RNA copy numbers (mean ± S.D.) at di
6 h 12 h
Control 228.4 ± 3.9 5838.1 ± 414.1
SARSi-R 86.1 ± 10.9 124.2 ± 5.1
SARSi-S 78.4 ± 10.2 1196.4 ± 56.1
SARSi-E 84.2 ± 16.8 2084.5 ± 128.3
SARSi-M1 95.4 ± 32.8 2256.9 ± 551.8
SARSi-M2 104.6 ± 5.1 2110.8 ± 222.3
SARSi-N 110.8 ± 10.9 2163.9 ± 487.3
Note. The viral genomic RNA copy numbers at 1 h post-infection was deﬁntion. In these experiments, 0, 1, 5, 20, 80, and 200 nM of SCoV
speciﬁc siRNAs were used in the transfection reaction mix-
tures. GL2i was used as a carrier, to normalize transfection
eﬃciency. The same dosage of total siRNAs (200 nM) was
maintained in each transfection. The viral titers in the media
were measured by TCID50 assay 24 h post-infection. At doses
of 1, 5, 20, 80, or 200 nM of SARSi-R in the transfection mix-
tures, the viral titer was reduced by 4.8, 16.6, 22.2, 25.4, and
33.4-folds, respectively (Fig. 5). Similarly, viral titers were re-
duced 3.1, 5.3, 10.5, 15.7 and 23.4-folds at doses of 1, 5, 20,
80, and 200 nM of SARSi-S, respectively. Similar results were
obtained from SARSi-E, SARSi-M1 and SARSi-M2. SARSi-
N showed lower relative activities at diﬀerent dosages (Fig. 5).
3.5. Synergistic inhibitory eﬀects of siRNAs combinations at low
dose
It has been shown that there is a saturated siRNA concen-
tration and combinations of siRNAs against the same gene
would not increase the antiviral activities [32,36]. An interest-
ing question was that whether synergistic antiviral eﬀects
would be achieved with combined siRNAs targeting diﬀerent
genes at lower doses. If so, it would oﬀer an opportunity to de-
velop cost-eﬀective and speciﬁc agents to combat SARS out-
break and drug resistance in the future.
To answer this question, we ﬁrst reduced the concentration
of siRNA from 200 to 50 nM in the transfection mixtures with-
out carrier siRNA and observed their antiviral eﬀects by
TCID50 assays. Lower inhibitory eﬀects were observed (data
not shown). When the concentration was further decreasedﬀerent time points
18 h 24 h
10680 ± 782.3 29709.3 ± 1628
186.4 ± 27.3 2159.8 ± 88.9
1903 ± 372.2 12152.2 ± 2060.8
3012 ± 65.3 12482.8 ± 612.7
3024.3 ± 124.7 11337.6 ± 834.5
4263.5 ± 243.1 8916.0 ± 91.1
5618.4 ± 144.9 14477.9 ± 877.7
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Fig. 5. Dose-dependent inhibition of SCoV reproduction by siRNAs. Diﬀerent amounts of siRNAs targeting SCoV and unrelated siRNA GL2i (for
normalization of transfection eﬃciency) were transfected into FRhk-4 cells. At 24 h post-transfection the viral titers in the conditioned media were
measured by back-titration. The value of control (GL2i only) was deﬁned as 100. The values (means ± S.D.) represent the average from the three
independent experiments.
2418 M.-L. He et al. / FEBS Letters 580 (2006) 2414–2420to 10 nM, the viral titer was reduced only about 5-folds
by SASRi-R, 8-folds by SARSi-E, 2-folds by SARSi-S, -M1
or -M2, respectively (Fig. 6).0
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Fig. 6. The eﬀects of combined siRNAs. A single siRNA (10 nM), two
combined siRNAs (5 nM each siRNA) were transfected into FRhk-4
cells. At 6 h post-transfection the medium was removed and the cells
were infected with SCoV suspended in DMEM for 1 h. Then the
medium was replaced with DMEM with 1% of FBS. At 24 h post-
infection the viral titers in the conditioned medium were determined by
virus infectivity assay. The viral titer of GL2i samples was deﬁned as
100. The values (means ±S.D.) represent the average from three
independent experiments.It was intriguing whether anti-SCoV eﬀects could be restored
with two siRNAs targeting diﬀerent genes at lower doses, be-
cause it would overcome the major cost barrier for clinic set-
tings. To test this possibility, we transfected either a single
siRNA or two siRNAs into FRhk-4 cells, and investigated
their anti-SARS activities. In these experiments, the same total
dosage of siRNAs (10 nM) was used for the transfection
regardless of one or two siRNAs. We measured the viral titers
in the conditioned media by TCID50 assay 24 h post-infection.
In experiments using a combination of two siRNAs, inhibition
was signiﬁcantly increased. Compared with the control, the
viral titers were reduced over 50-fold for SARSi-R/-S and
SARSi-S/-E combinations, about 18-fold for SARSi-R/-M1
and SARSi-S/-M2 combinations, and over 30-fold for SAR-
Si-R4/-E combinations, respectively.4. Discussion
The SARS-associated coronavirus is a novel identiﬁed RNA
virus, which poses a severe threat to human health as there is a
large SCoV-like virus pool in a number of animal species [1–
18]. Currently, the knowledge on SCoV is limited. In this pa-
per, we report the anti-viral eﬀects and genomic RNA kinetics
of eﬀective siRNAs targeting diﬀerent functional genes, and
M.-L. He et al. / FEBS Letters 580 (2006) 2414–2420 2419synergistic antiviral eﬀects at very low dose when two siRNAs
against diﬀerent genes were used in combination. These ﬁnd-
ings may combat SCoV resistance to a single siRNA via fast
mutagenesis and pave a way for the development of cost-eﬀec-
tive siRNA agents for anti-SARS treatment.
Speciﬁc siRNAs targeted SCoV genomic RNA would lead
to viral RNA cleavage in the host cells. We previously identi-
ﬁed eﬀective siRNAs targeting rep gene which markedly re-
duced intracellular viral genomic RNA level [36]. In this
study, we showed that siRNAs targeting S/E/M structural
genes also inhibited viral RNA accumulation in host cells with
lower eﬃciency (Fig. 4) while exhibited almost the same inhib-
itory activities for viral reproductions (Fig. 5). There may be
several reasons for this phenomenon. First, viral genomic
RNA will be immediately translated into viral proteins and
undergo a fast RNA replication phase (as measured by time-
point experiments) when it enters the cells. Replicase is en-
coded by viral genomic RNA and directly responsible for viral
RNA synthesis. Therefore, siRNA targeting the replicase re-
gion will directly reduce replicase. Secondly, the 3 0-region of
viral genomic RNA encodes several subgenomic mRNAs.
The subgenomic mRNAs are abundant in the host cells [21–
25], which may reduce target eﬃciency or prolongs the time
to cleavage of viral genomic RNA. Finally, active transcription
and/or translation in the 3 0-region of viral genomic RNA may
block the siRNA target sites. However, the structural gene
products directly contribute to impact viral package and infec-
tious activities. The accumulated infectious viruses rely on
both replication, and correct and eﬀective package. Therefore,
SARSi-S/-E/-M1/-M2 could display similar inhibitory activi-
ties for production of infectious virions to SARSi-R at a satu-
rate concentration in the media.
Kinetics studies showed that RNA replication took place in
two phases: a rapid replication phase (1–12 h), and a slow rep-
lication phase (12–24 h). In the ﬁrst 12 h, the viral genomic
RNA increased near 6000-fold. However, viral genomic
RNA increased only 4–6-fold in the next 12 h (Table 1). Viral
genomic RNA replication was not potently inhibited in the
ﬁrst six hours post-infection in cells transfected with speciﬁc
siRNAs targeting any of functional genes, for unknown rea-
sons (Fig. 4). Viral RNA accumulation was almost completely
inhibited in cells transfected with SARSi-R until 18 h post-
infection. Viral RNA copies were also increasingly multiplied
in cells transfected with other speciﬁc siRNA (2–5-fold) from
6 to 12 h and from 12 to 18 h post-infection. The copies of viral
genomic RNA increased faster in cells between 18 and 24 h
post-infection in some cases (SARSi-R, and -S). These results
suggested that the transfected siRNAs in FRhk-4 cells had a
relatively short half-life. Therefore, a sustained expression of
shRNA via viral vectors, e.g. adenovirus-based short-term
expression vectors, would oﬀer an alternative for anti-SARS
therapy.
Various combinations of siRNAs targeting diﬀerent genes
may produce synergistic anti-SCoV eﬀects, as diﬀerent genes
play distinguishing functions in viral life cycles. We did not ob-
serve obvious synergistic anti-SCoV eﬀects when two or three
eﬀective siRNAs targeted on the replicase region [32]. In this
study, we showed that speciﬁc siRNAs at low concentrations
with highly concentrated carrier siRNA (total siRNAs main-
tained as 200 nM, Fig. 5) exhibited potent anti-SCoV activity.
As we know, DNA or RNA carrier reagents would increase
transfection eﬃciency and extend the life of transfectedDNA or RNA in the cells. Therefore, we ﬁrst investigated
whether siRNAs would display similar antiviral activities at
lower doses without carrier siRNA. We found that a single
siRNA at a low concentration (10 nM) without carrier siRNA
signiﬁcantly reduced antiviral activities while combination of
two siRNAs targeting diﬀerent functional genes displayed syn-
ergistic antiviral activities (Fig. 6). Considering that SARSi-R,
-S, -M1 and -M2 could only repress viral reproduction about
2–5-fold at 10 nM concentration, and combined siRNAs
against two diﬀerent genes exhibited over 18–50-fold reduc-
tion, these combinations are very eﬀective. These results sug-
gested that combinations of eﬀective siRNAs targeting
diﬀerent genes could be used in clinical applications with re-
duced toxicity at a lower cost.
Our results demonstrated that siRNAs targeting function-
distinguishing structural genes achieved varying degrees of suc-
cess in inhibiting viral genomic RNA accumulation in host
cells but reducing viral titers almost to a same level as eﬀective
siRNA targeting replicase gene. In addition, we also showed
that siRNAs targeting rep, S, E, and M genes at very low con-
centration displayed synergistic activities that restored even
displayed better antiviral activities than a single siRNA alone
at saturated concentration. Our previous study showed that
spike protein would be a good target for anti-SARS drug
development and siRNA exhibited synergistic antiviral eﬀects
with chemical drugs [28,35]. Taking together, we suggest that
replicase, spike protein, envelope protein and membrane pro-
tein would be served as targets for siRNAs/shRNAs delivered
with vectors (e.g., adenoviral vectors) for inhibition of viral
replication and infections.
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